Each capsule contains: Clindamycin (as Hydrochloride) 150 mg or 300 mg.
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive organisms and a wide range of anaerobic pathogens, as well as some antiprotozoal actions. It is used usually where other drugs are unsuitable, in the treatment of anaerobic, staphylococcal, and streptococcal infections, and in the prophylaxis of endocarditis. It has also been tried in protozoal infections such as Pneumocystis carinii pneumonia or toxoplasmosis. It is given by mouth as the hydrochloride or palmitate hydrochloride, or parenterally as the phosphate. It is also applied in the treatment of acne.
Pharmacology: Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive and a wide range of anaerobic bacteria.
Pharmacodynamics: Mechanisms of action: Lincosamides such as Clindamycin bind to 50s sub unit of the bacterial ribosome similarly to macrolides such as erythromycin and inhibits the early stages of protein synthesis. The action of Clindamycin is predominantly bacteriostatic although high concentrations may be slowly bactericidal against sensitive strains.
Spectrum of activity: It is active against most anaerobic Gram-positive bacteria including streptococci, staphylococci, Bacillus anthracis, and Corynebacterium diphtheriae, enterococci, however, are generally resistant.
Clindamycin has a good activity against a wide range of anaerobic bacteria. Susceptible Gram-positive anaerobes include Eubacterium, Propionibacterium, Peptococcus, (although F. varium is actually resistant, Veillonella, and Bacteroides spp. including the B. fragilis group.
Pharmacokinetics: About 90% of a dose of Clindamycin hydrochloride is absorbed from the gastrointestinal tract; concentrations of 2 to 3 μg per mL occur within 1 hour after a 150 mg dose of Clindamycin, with average concentrations of about 0.7 μg per mL after 6 hours. After doses of 300 and 600 mg peak plasma concentrations of 4 and 8 μg per mL, respectively, have been reported. Absorption is not significantly diminished by food in the stomach but the rate of absorption may be reduced.
For the treatment of anaerobic infections outside the CNS; alternative treatment for staphylococcal and streptococcal (except enterococcal) infections in patients allergic to penicillins and cephalosporins; alternative treatment for Actinomycosis, Gardnerella vaginalis vaginosis, toxoplasmosis, and Pneumocystis carinii pnemonia; as prophylaxis for bacterial endocarditis for cardiac patients who are allergic to penicillin prior to certain dental, oral, or esophageal procedures.
Adult: Mild to moderate infections: 150-300 mg capsule every 6 hours.
Severe infections: 450 mg capsule every 6 hours.
Children may be given 3 to 6 mg/kg body weight every 6 hours; those under one year old or weighing 10 kg or less should receive at least 37.5 mg every 8 hours. Or as prescribed by the physician.
Diarrhea and inflammatory bowel disease.
Hypersensitivity to Clindamycin or any component.
Clindamycin should not be given to patients hypersensitive to it or the closely-related drug lincomycin. It should be used with caution in patients with gastro-intestinal disease, particularly those with a history of colitis. Periodic tests of liver function and blood have been recommended in patients receiving prolonged therapy, and in infants. Clindamycin is excreted in breast milk and breast-feeding should be avoided during therapy. Adjust dosage in patients with impaired hepatic functions. Discontinue immediately if diarrhea or colitis develops.
diarrhea, pseudomembranous colitis, nausea, vomiting.
elevation of liver enzymes.
eosinophilia, neutropenia, granulocytopenia, thrombocytopenia.
Store at temperatures not exceeding 30°C.
J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.
Cap 150 mg x 100's. 300 mg x 100's.